$NTRA

Chapman Steven Leonard sold $1.5M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 6,500 shares of Natera, Inc. (NTRA) at $223.34 ($1.45M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not, by itself, indicate a change in business outlook or new fundamental information.

02

Market read

Traders may treat this as a low-signal sentiment input rather than a standalone catalyst.

03

What to watch

The filing date (June 5) may lag the actual sale (June 4), and the disclosed sale price may already be reflected in trading if the market anticipated routine 10b5-1 activity.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5 for a June 4 sale

Background

SEC Form 4 reports insider transactions by officers/directors; 10b5-1 plans are pre-arranged trading schedules intended to reduce timing-based inference.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $1.45M of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

This is an SEC Form 4 insider transaction with disclosed price/size, but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically dampens interpretive value.

Market effects

Minimal; this is company-specific insider execution rather than a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with management caution or liquidity needs; traders may watch for follow-on sales.

Key entities

  • Natera, Inc.

    Subject of the insider sale; CEO and President sold 6,500 shares for ~$1.45M under a 10b5-1 plan.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.